This website uses cookies. For more information please contact us or consult our privacy policy.

Your binder contains too many pages, the maximum is 40.

We are unable to add this page to your binder, please try again later.

This page has been added to your binder.

Michael Kennedy
Michael N. Kennedy
Partner
Washington +1 202 662 5215 mkennedy@cov.com Download V-card

Mike Kennedy is a litigator with substantial trial experience, representing clients before federal district and appellate courts.

In particular, Mr. Kennedy has extensive experience representing pioneer pharmaceutical companies in patent litigation. Over the past several years, he has represented such companies in over a dozen Hatch-Waxman actions in therapeutic areas ranging from oncology to sleep medicine, at all stages of litigation including trial and appeal. He has also participated in district court and Patent Office proceedings involving biologic drug patents.

  • Purdue Pharma L.P. and Transcept Pharmaceuticals in Hatch-Waxman patent litigation against several generic drug companies involving Intermezzo®, a drug for the treatment of insomnia. Played a leading role in ten-day, three-patent, three-defendant trial (D.N.J.).
  • Leading pioneer pharmaceutical company in Hatch-Waxman patent litigation against several generic drug companies involving a drug indicated to reduce the risk of COPD exacerbations (D.N.J.).
  • Amarin in Hatch-Waxman patent litigation against several drug companies involving Vascepa®, a prescription medicine used (along with a low-fat and low-cholesterol diet) to lower very high levels of triglycerides in adults (D.N.J. and Fed. Cir.).
  • Leading pioneer pharmaceutical company in Hatch-Waxman patent litigation against several generic drug companies involving a drug for treating ulcerative colitis (E.D. Tex.).
  • Pioneer pharmaceutical company in district court and inter partes review proceedings involving a patent covering a method of treating certain types of cancer (E.D. Pa., P.T.O.).
  • Pioneer pharmaceutical company in inter partes review proceedings concerning company’s patents listed in Orange Book for onychomycosis treatment (P.T.O).
  • BioHorizons in related contract and inventorship disputes involving patents pertaining to dental implant system technology. Obtained summary judgment in contract dispute, affirmed on appeal(S.D. Fla., Fed. Cir., 11th Cir.).
  • Warner Chilcott as member of trial team that obtained a judgment upholding the validity of the patent covering Lo Loestrin®, an oral contraceptive. The judgment was affirmed by the Federal Circuit (D.N.J.).
  • Pioneer pharmaceutical company in two separate patent cases, each involving allegations that the company induces infringement of a method of treatment patent by marketing its best-selling cholesterol-lowering drug (D.S.C.).
  • Leading information technology company in commercial litigation against former subcontractor. Obtained summary judgment on eve of trial (N.Y. Supreme Court).
  • Sanofi in Hatch-Waxman patent litigation involving Taxotere®, a drug used to treat several forms of cancer (D. Del.).
  • Knowles Electronics in multiple patent infringement actions in the ITC, and a related district court action (ITC, N.D. Ill.).

Pro Bono

  • Representing a group of pet owners seeking to compel a local animal shelter to follow the county code regarding the humane treatment of animals.
  • Representation of a defendant accused of murder in a case tried to a jury in Prince George’s County, Maryland.
  • Successful representation of an applicant for Social Security disability benefits.
  • Washington DC Super Lawyers, IP Litigation "Rising Star" (2014-2016)